BCRX

BioCryst Pharmaceuticals, Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$7.68

Price (1 Year)

$10.45 $6.38

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %49 / %30
Non-compliant assets / Total market cap %19.9 / %30
Non-compliant revenue / Total income %1.4 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE.

Website

Analysis (Turkish): BCRX Hissesi Caiz mi, Helal mi? BioCryst Pharmaceuticals, Inc. Katılım Analizi